文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.

作者信息

Vyas S P, Kannan M E, Jain Sanyog, Mishra V, Singh Paramjit

机构信息

Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Sagar, MP 470 003, India.

出版信息

Int J Pharm. 2004 Jan 9;269(1):37-49. doi: 10.1016/j.ijpharm.2003.08.017.


DOI:10.1016/j.ijpharm.2003.08.017
PMID:14698575
Abstract

The present study was aimed at preparation, characterization, and performance evaluation of rifampicin-loaded aerosolized liposomes for their selective presentation to alveolar macrophages, that being the most dense site of tuberculosis infection. Egg phosphatidylcholine (PC)- and cholesterol (Chol)-based liposomes were modified by imparting negative charge (using dicetylphosphate, DCP) or by coating them with alveolar macrophage-specific ligands (maleylated bovine serum albumin, MBSA; and O-steroyl amylopectin, O-SAP). The prepared formulations were characterized in vitro for vesicle morphology, mean vesicle size, and percent drug entrapment. Pressurized packed systems based on preformed liposomal formulations in chlorofluorocarbon aerosol propellants were prepared. In vitro airway penetration efficiency of the liposomal aerosols was determined by percent dose reaching the base of the lung, it was recorded 1.5-1.8 times higher as compared to plain drug solution-based aerosol. Percent viability of Mycobacterium smegmatis inside macrophages (in vitro) after administration of drug (in vivo) was in the range of 7-11% in the case of ligand-anchored liposomal aerosols, while it was recorded to be 45.7 and 31.6% in case of plain drug and plain neutral liposomal aerosol (based on PC:Chol)-treated macrophages. Results suggest the preferential accumulation of MBSA- and O-SAP-coated formulations in the lung macrophages, which was further reflected in the periodically monitored in vivo tissue distribution studies. Higher lung drug concentration was recorded in case of ligand-anchored liposomal aerosols and negatively charged liposomal aerosols (based on PC:Chol:DCP) as compared to plain drug and plain liposome-based aerosols. The drug was estimated in the lung in high concentration even after 24h. The drug localization index calculated after 6h was nearly 1.4- and 3.5-fold, respectively, for both ligand-appended liposome-based systems as compared to negatively charged and plain neutral liposome-based aerosolized systems. These results suggest that the ligand-anchored liposomal aerosols are not only effective in rapid attainment of high-drug concentration in lung with high population of alveolar macrophages but also maintain the same over prolonged period of time. The significance of targeting potential of the developed systems was established.

摘要

相似文献

[1]
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.

Int J Pharm. 2004-1-9

[2]
Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages.

Int J Pharm. 2005-5-30

[3]
Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation.

J Liposome Res. 2009

[4]
Liposome-based drug delivery to alveolar macrophages.

Expert Opin Drug Deliv. 2007-3

[5]
Ligand directed macrophage targeting of amphotericin B loaded liposomes.

Int J Pharm. 2000-12-4

[6]
In-situ formation of liposome of rifampicin: better availability for better treatment.

Curr Drug Deliv. 2009-10

[7]
One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.

J Control Release. 2009-4-2

[8]
Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.

J Aerosol Med Pulm Drug Deliv. 2016-4

[9]
Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery.

Pharm Res. 2015-5

[10]
Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.

J Aerosol Med Pulm Drug Deliv. 2017-5-16

引用本文的文献

[1]
Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections.

Antibiotics (Basel). 2025-7-20

[2]
Formulation and clinical translation of inhalable nanomedicines for the treatment and prevention of pulmonary infectious diseases.

Drug Deliv Transl Res. 2025-4-29

[3]
Inhalable biohybrid microrobots: a non-invasive approach for lung treatment.

Nat Commun. 2025-1-14

[4]
Optimization, characterization, and cytotoxicity studies of novel anti-tubercular agent-loaded liposomal vesicles.

Sci Rep. 2024-1-4

[5]
Macrophage-Targeted Lipid Nanoparticle Delivery of microRNA-146a to Mitigate Hemorrhagic Shock-Induced Acute Respiratory Distress Syndrome.

ACS Nano. 2023-9-12

[6]
In Vitro Evaluation of Aerosol Therapy with Pentamidine-Loaded Liposomes Coated with Chondroitin Sulfate or Heparin for the Treatment of Leishmaniasis.

Pharmaceutics. 2023-4-6

[7]
Studies of the Specific Activity of Aerosolized Isoniazid against Tuberculosis in a Mouse Model.

Antibiotics (Basel). 2022-11-1

[8]
A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation.

Drug Deliv Transl Res. 2023-5

[9]
Meta-Analysis of Drug Delivery Approaches for Treating Intracellular Infections.

Pharm Res. 2022-6

[10]
Nano-in-Microparticles for Aerosol Delivery of Antibiotic-Loaded, Fucose-Derivatized, and Macrophage-Targeted Liposomes to Combat Mycobacterial Infections: In Vitro Deposition, Pulmonary Barrier Interactions, and Targeted Delivery.

Adv Healthc Mater. 2022-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索